Accès gratuit
| Numéro |
Med Sci (Paris)
Volume 25, Numéro 12, Décembre 2009
Anticorps monoclonaux en thérapeutique
|
|
|---|---|---|
| Page(s) | 1116 - 1120 | |
| Section | II - La réalité clinique | |
| DOI | https://doi.org/10.1051/medsci/200925121116 | |
| Publié en ligne | 15 décembre 2009 | |
- Marasco WA, Sui J. The growth and potential of human antiviral monoclonal antibody therapeutics. Nat Biotechnol 2007; 25 : 1421–34. [Google Scholar]
- Ledford H. Monoclonal antibodies come of age. Nature 2008; 455 : 437. [Google Scholar]
- Dau B, Holodniy M. Novel targets for antiretroviral therapy: clinical progress to date. Drugs 2009; 69 : 31–50. [Google Scholar]
- Trkola A, Kuster H, Rusert P, et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 2005; 11 : 615–22. [Google Scholar]
- Hessell AJ, Hangartner L, Hunter M, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007; 449 : 101–4. [Google Scholar]
- Karlsson Hedestam GB, Fouchier RA, Phogat S, et al. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol 2008; 6 : 143–55. [Google Scholar]
- Reichert JM, Dewitz MC. Anti-infective monoclonal antibodies: perils and promise of development. Nat Rev Drug Discov 2006; 5 : 191–5. [Google Scholar]
- Simmons CP, Bernasconi NL, Suguitan AL, et al. Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med 2007; 4 : e178. [Google Scholar]
- Yu X, Tsibane T, McGraw PA, et al. Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature 2008; 455 : 532–6. [Google Scholar]
- Mansbach J, Kunz S, Acholonu U, et al. Evaluation of compliance with palivizumab recommendations in a multicenter study of young children presenting to the emergency department with bronchiolitis. Pediatr Emerg Care 2007; 23 : 362–7. [Google Scholar]
- Wu H, Pfarr DS, Johnson S, et al. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol 2007; 368 : 652–5. [Google Scholar]
- De Kruif J, Bakker AB, Marissen WE, et al. A human monoclonal antibody cocktail as a novel component of rabies postexposure prophylaxis. Annu Rev Med 2007; 58 : 359–68. [Google Scholar]
- Soares MM, King SW, Thorpe PE. Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases. Nat Med 2008; 14 : 1357–62. [Google Scholar]
- Reichert JM. Trends in the development and approval of monoclonal antibodies for viral infections. BioDrugs 2007; 21 : 1–7. [Google Scholar]
- Oliphant T, Engle M, Nybakken GE, et al. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med 2005; 11 : 522–30. [Google Scholar]
Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.
Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.
Le chargement des statistiques peut être long.